Stem Cell Cure for Diabetes: Where We Stand in 2026

Diabetes Research · 5 · February 4, 2026

In February 2026, a 25-year-old patient at Peking University became insulin-independent 75 days after receiving iPSC-derived beta cells. His own cells, reprogrammed, transplanted back. No donor. No immunosuppression. Published in Nature Medicine.

That is the closest thing to a Type 1 diabetes cure that has ever existed. But — and this is a significant but — it is one patient. One. Here is the full picture.

The 5 Trials That Matter

China iPSC (Peking University): The headline case. Autologous iPSCs — patient's own cells reprogrammed into beta cells. Eliminates immune rejection entirely. Status: clinical success in one patient. The question: can it be replicated at scale? The cell manufacturing process took months and cost is estimated at $500,000+.

Vertex VX-264 (Encapsulated Islets): 8 of 14 patients achieved insulin independence at 18 months. Published in NEJM, January 2026. FDA Breakthrough Therapy designation. The encapsulation device protects cells from immune attack — no immunosuppression needed. Phase III underway. This is the trial most likely to produce a commercial therapy within 3–5 years.

ViaCyte/CRISPR (Gene-Edited Beta Cells): CRISPR-edited cells that the immune system cannot recognize. No encapsulation device, no immunosuppression. Preclinical. Human trials planned for late 2026.

Sernova Cell Pouch (Toronto): A small implantable pouch that houses donor islet cells. 4 patients maintained insulin production for 12+ months without systemic immunosuppression. Phase I/II.

Japan Autologous iPSC for Type 2 (Kyoto University): Using patient-derived cells to restore beta cell function in Type 2 — a different approach since Type 2 involves resistance, not just destruction. Phase I. Improved C-peptide levels reported January 2026.

What It Costs

In the US, stem cell therapies for diabetes are estimated at $80,000–$300,000. In India, five NABH-accredited centers offer MSC (mesenchymal stem cell) therapies for $8,000–$15,000 — not the same as iPSC transplants, but legitimate therapies showing 0.5–1.0% HbA1c improvements in Type 2 trials.

Our Stem Cell Hub tracks every active trial with real NCT identifiers, eligibility criteria, and enrollment status. You can bookmark trials you qualify for and get notified when their status changes. There is also a cost comparison between Indian clinics and US pricing, and an inquiry form if you want to explore treatment at Medanta, StemRx, or Plexus centres.

Track active trials and bookmark the ones you qualify for at Clinical Trials.